ACDC (medicine)

From WikiMD's Medical Encyclopedia

Revision as of 05:18, 25 March 2025 by Prab (talk | contribs)
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)

Rare genetic disorder causing arterial and joint calcification


Arterial calcification due to deficiency of CD73
Synonyms ACDC, CD73 deficiency
Pronounce N/A
Specialty N/A
Symptoms Arterial calcification, joint stiffness, chronic pain
Complications Peripheral artery disease, claudication, mobility impairments
Onset Typically early to mid-adulthood
Duration Lifelong
Types
Causes Mutation in the NT5E gene
Risks Family history, genetic predisposition
Diagnosis Genetic testing, radiographic imaging
Differential diagnosis Pseudoxanthoma elasticum, vascular calcification, arteriosclerosis
Prevention None
Treatment Symptomatic; investigational use of adenosine or phosphatase inhibitors
Medication Experimental therapies
Prognosis Progressive, but not typically life-threatening
Frequency Extremely rare
Deaths Rare, related to cardiovascular complications


Arterial calcification due to deficiency of CD73 (ACDC) is a rare genetic disorder characterized by abnormal calcium deposits in the arteries and joints, especially in the lower limbs. The condition results from mutations in the NT5E gene, which encodes the CD73 enzyme that plays a crucial role in purine metabolism and the regulation of vascular calcification.

History[edit]

Although patients with symptoms consistent with ACDC were first documented as early as 1914, the disorder remained poorly understood for nearly a century. It was not until 2011 that researchers were able to pinpoint the exact genetic cause: mutations in the NT5E gene that lead to a deficiency of CD73 enzyme activity.

Genetics[edit]

ACDC is caused by autosomal recessive mutations in the NT5E gene located on chromosome 6. This gene encodes the CD73 enzyme, which is involved in converting adenosine monophosphate (AMP) to adenosine. In individuals with ACDC, the deficiency in CD73 leads to a reduction in adenosine production, which normally plays a role in inhibiting vascular and soft tissue calcification.

Pathophysiology[edit]

In the absence of CD73 function, the molecular pathways that prevent calcium phosphate deposition in the vasculature are impaired. This results in progressive calcification of medium- and small-sized arteries and periarticular tissues, particularly in the hands, feet, and lower extremities.

Clinical presentation[edit]

The main symptoms of ACDC include:

Diagnosis[edit]

ACDC diagnosis is confirmed by:

  • Clinical evaluation of symptoms
  • Imaging studies such as X-rays, CT scans, or MRI that reveal calcified arteries and joints
  • Genetic testing to identify mutations in the NT5E gene

Treatment[edit]

There is currently no cure for ACDC. Treatment is symptomatic and may include:

  • Pain management using analgesics
  • Surgical intervention to remove calcified deposits or improve blood flow
  • Physical therapy to preserve mobility and reduce stiffness

Experimental therapies[edit]

Recent molecular studies have demonstrated that treatment with adenosine or phosphatase inhibitors in laboratory models may reverse or prevent calcification associated with CD73 deficiency. These findings are preliminary but offer hope for future therapeutic development.

Prognosis[edit]

ACDC is a progressive condition that can significantly impact quality of life, particularly due to pain and reduced mobility. However, it is generally not life-threatening unless significant vascular complications develop.

Epidemiology[edit]

ACDC is an extremely rare disorder, with fewer than 20 families described in medical literature as of the 2020s. The true prevalence is unknown due to underdiagnosis and lack of awareness.

See also[edit]

External links[edit]



NIH genetic and rare disease info[edit]

ACDC (medicine) is a rare disease.




This article is a medical stub. You can help WikiMD by expanding it!
PubMed
Wikipedia
Navigation: Wellness - Encyclopedia - Health topics - Disease Index‏‎ - Drugs - World Directory - Gray's Anatomy - Keto diet - Recipes

Ad. Transform your health with W8MD Weight Loss, Sleep & MedSpa

W8MD's happy loser(weight)

Tired of being overweight?

Special offer:

Budget GLP-1 weight loss medications

  • Semaglutide starting from $29.99/week and up with insurance for visit of $59.99 and up per week self pay.
  • Tirzepatide starting from $45.00/week and up (dose dependent) or $69.99/week and up self pay

✔ Same-week appointments, evenings & weekends

Learn more:

Advertise on WikiMD


WikiMD Medical Encyclopedia

Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.